Genetic Delivery of Monoclonal Antibodies for Prevention and Cure of HIV
June 14, 2018
Location
5601 Fishers Lane, Room 1D13, Rockville, Maryland
Objectives of the Meeting
- To review current developments and identify challenges in the field of genetic delivery of monoclonal antibodies against HIV
- To discuss strategies for achieving sustained therapeutic levels of monoclonal antibodies after gene delivery for prophylaxis and virologic remission of HIV
Sponsored by
National Institute of Allergy and Infectious Diseases
AGENDA
Thursday, June 14, 2018
| Time | Agenda Item |
|---|---|
| 7:30 am-8:30 am | Registration and Security Clearance |
| 8:30 am-8:40 am | Opening Remarks and Meeting Goals Michael Pensiero / Maria Chiuchiolo (Division of AIDS/NIAID) |
| 8:40 am-10:40 am |
Session 1: Challenges for Clinical Development of Adeno- Associated Vector (AAV) Antibody Delivery Chair: James M. Wilson (University of Pennsylvania) Session goals:
|
| 8:40 am-8:50 am | Introduction James M. Wilson (University of Pennsylvania) |
| 8:50 am-9:10 am | A Phase 1 Trial of AAV1 Vectored Immunoprophylaxis for HIV Frances Priddy (International AIDS Vaccine Initiative) |
| 9:10 am-9:30 am | Use of an AAV8 Vector for Transgene Delivery of VRC 07; An Overview of VRC 603 Joseph Casazza (Vaccine Research Center, NIAID) |
| 9:30 am-9:50 am | Optimization of Venous Limb Perfusion with rAAV for Expression of Secreted Proteins from Muscle and Induction of Peripheral Treg Responses Terence Flotte (University of Massachusetts Medical School) |
| 9:50 am-10:10 am | Investigational AAV Gene Therapy for Potential Treatment of Hemophilia B Daniel Takefman (Spark Therapeutics) |
| 10:10 am-10:40 am | Panel Discussion Invited Panelist: Suzanne Epstein (FDA/CBER) |
| 10:40 am-11:00 am | Break |
| 11:00 am-1:00 pm |
Session 2: Viral Vectored Delivery of Monoclonal Antibodies in Pre-clinical Development– Strategies Moving Forward Chair: Phil Johnson (Biotechnology Consultant) Session goal:
|
| 11:00 am-11:10 am | Introduction Phil Johnson (Biotechnology Consultant) |
| 11:10 am-11:30 am | The Potential of AAV Vector for Long-Term Delivery Ron Desrosiers (University of Miami) |
| 11:30 am-11:50 am | Pre-Clinical Assessment of Vectored Immunoprophylaxis Against HIV in Humanized Mice Alex Balazs (Ragon Institute) |
| 11:50 am-12:10 pm | Properties of AAV-eCD4-Ig Useful for Prevention and Reservoir Reduction Michael Farzan (The Scripps Research Institute) |
| 12:10 pm-12:30 pm | The NHP/SIV Model for AAV-Mediated Protection Against HIV Infection Mario Roederer (Vaccine Research Center, NIAID) |
| 12:30pm-1:00pm | Panel Discussion Invited Panelist: Mark A. Kay (Stanford University) |
| 1:00 pm-2:00 pm | Lunch Break |
| 2:00 pm-4:20 pm |
Session 3: Non-viral Expression Platforms for Delivery of Monoclonal Antibodies Chairs: Drew Weissman and David Weiner Session goal:
|
| 2:00 pm-2:25 pm | Engineering Synthetic Plasmid DNA (DMAb) for In Vivo Antibody Delivery David Weiner (The Wistar Institute) |
| 2:25 pm-2:45 pm | Novel dMAbTM Platform Technology for the Delivery of DNA- Encoded Monoclonal Antibodies Kate Broderick (Inovio Pharmaceuticals) |
| 2:45 pm-3:10 pm | Nucleoside-Modified mRNA Therapeutic Delivery Drew Weissman (University of Pennsylvania) |
| 3:10 pm-3:30 pm | mRNA-Encoded Antibodies for Passive Immunization Frédéric Chevessier-Tünnesen (CureVac AG) |
| 3:30 pm-3:50 pm | mRNA Delivery of Therapeutic Antibodies: HIV and Chikungunya Elisabeth Narayanan (Moderna Therapeutics) |
| 3:50 pm-4:20 pm | Panel Discussion Invited Panelists: Ruxandra Draghia (Merck, Global Vaccines) JoAnn Suzich (MedImmune) |
| 4:20 pm-4:30 pm | Closing Remarks Michael Pensiero (NIAID/ Division of AIDS, NIAID) |
| 4:30 pm | Adjourn |